BioSig Technologies, Inc. (NASDAQ:BSGM) CEO Kenneth Londoner tells Proctive the Westport, Connecticut-based group has formed three new evaluation agreements for the PURE EP System, its novel electrophysiology (EP) signal acquisition and analysis technology.
Londoner says new clinical sites due to receive BioSig’s PURE EP System include New York-Presbyterian/Weill Cornell Medical Center, Michigan Medicine–University Hospital, and Houston Methodist Hospital. New installations of the PURE EP System will now follow a shorter assessment cycle of 90 days based on favorable data from installation evaluations in 2020.